The United Nations, the International Children's Emergency Fund (UNICEF), has said that under a "massive operation", nearly 2 billion doses of the coronavirus vaccine will be delivered to developing countries next year.
It should be noted that world leaders have pledged to ensure the transparent distribution of vaccines against the deadly coronavirus, which has spread around the world.
In a statement, UNICEF said it was working with the World Health Organization (WHO) to provide vaccines and one billion syringes to poor countries such as Burundi, Afghanistan, and Yemen under the Global Code-19 Vaccine Allocation Plan, COVAX. Is working with more than 350 airlines and freight companies to supply.
"This invaluable cooperation will go a long way in ensuring that there is ample transport capacity for this historic and very large operation," UNICEF Director of Supply Division Ateliva Cadelli said in a statement.
According to a report by the British news agency 'Reuters', Kovex is being jointly led by the GAVI Vaccine Group, the World Health Organization, and the Coalition for the Prevention of Infectious Diseases.
The aim is to discourage the government from stockpiling COD-19 vaccines and to focus on providing the first-risk vaccine to the most vulnerable in each country.
At the G20 summit later this week, leaders of the world's 20 economies pledged to ensure a uniform distribution of corona vaccines, drugs, and tests so that poor countries do not lag behind.
According to the World Health Organization, even before the global epidemic, about 20 million children did not have equal access to vaccines, leading to serious illness and death. Prevent disability and poor health.
"We need everyone to take this initiative because we are ready to provide more doses of the COD-19 vaccine, syringes, and more personal protective equipment to frontline workers around the world," he said.
She is currently working with the Pan American Health Organization and the International Air Transport Association.
With Quakes, UNICEF's role is as the world's largest buyer of vaccines.
They purchase more than 2 billion doses of routine immunizations annually, the statement said.
Pharmaceutical and research centers around the world are involved in the race to develop the Code-19 vaccine, and vaccine trials are underway with thousands of participants globally.
The Pfizer vaccine, with 95% success in the results of the last trials and no serious side effects, can now get emergency licenses from the United States and Europe by next month.
On the other hand, the Moderna vaccine released preliminary data last week, according to which the vaccine is 94.5% effective.
Both vaccines, which have performed better than expected, have been developed using new messenger RNA (mRNA) technology, which has raised hopes of eradicating the global epidemic that has so far killed 1.3 million people. While it has severely affected daily life and economies.
